GlassScriptPhysician profile
Bradley White
NPI 1396906491
$7,412.77
in general payments reported to CMS, 2019-2025
41 companies · $963 in 2025
The $963 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $1,043 · 2021: $1,258 · 2022: $1,023 · 2023: $1,152 · 2024: $1,071 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,283.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $867.24 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $701.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $429.60 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $412.51 | 2021-2025 | |
| Abbvie INC. | $370.97 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $353.55 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $287.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $280.39 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $273.39 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $253.33 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $191.87 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $180.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $124.76 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $110.76 | 2023-2024 | Quviviq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $104.32 | 2022 | |
| Antares Pharma, INC. | $101.52 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $97.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $92.27 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.94 | 2019-2024 | Xifaxan |
| Genentech USA, INC. | $77.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.71 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil |
| Exact Sciences Corporation | $70.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $65.13 | 2019-2025 | |
| Mylan Specialty L.P. | $52.51 | 2020-2024 | Yupelri |
| Astellas Pharma US INC | $50.30 | 2023-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $49.98 | 2020-2021 | |
| Amarin Pharma, INC. | $48.88 | 2020-2021 | |
| Allergan, INC. | $38.89 | 2020 | |
| Eisai INC. | $34.30 | 2020-2021 | |
| Dexcom, INC. | $33.27 | 2024-2025 | Dexcom G6 Transmitter |
| Portola Pharmaceuticals, LLC | $32.36 | 2019 | |
| Axsome Therapeutics, INC. | $28.67 | 2025 | Auvelity |
| C. R. Bard, INC. & Subsidiaries | $26.97 | 2023 | Purewick Female External Catheter |
| Biogen, INC. | $25.75 | 2022 | |
| Arbor Pharmaceuticals, INC. | $21.73 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.35 | 2021 | |
| Organogenesis INC. | $17.96 | 2024 | Puraply Am |
| Phathom Pharmaceuticals, INC. | $16.37 | 2024 | Voquezna |
| Ironshore Pharmaceuticals INC. | $16.10 | 2019 | |
| Shire North American Group INC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.